Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Hypotensive action methyldopa.

Literature DB >> 13993069

Hypotensive action methyldopa.

H SMIRK.

Abstract

Entities: Chemical Disease

Keywords: ANTIHYPERTENSIVE AGENTS

Mesh：

Substances：

Year: 1963 PMID： 13993069 PMCID： PMC2123381 DOI： 10.1136/bmj.1.5324.146

Source DB: PubMed Journal: Br Med J ISSN： 0007-1447

× No keyword cloud information.

9 in total

1. Clinical and chemical studies with alpha-methyl-dopa in patients with hypertension.

Authors: L GILLESPIE; J A OATES; J R CROUT; A SJOERDSMA
Journal: Circulation Date: 1962-02 Impact factor: 29.690

2. Clinical pharmacology of newer anthypertensive agents, monoamine oxidase and decarboxylase inhibitors, bretvlium tosvlate, and guanethidine.

Authors: L GILLESPIE
Journal: Ann N Y Acad Sci Date: 1960-10-11 Impact factor: 5.691

3. [Inhibition of DOPA decarboxylase by alpha-methyl-DOPA in vivo].

Authors: G REICHEL; H DENGLER
Journal: Naunyn Schmiedebergs Arch Exp Pathol Pharmakol Date: 1958

4. [Inhibition of serotonin formation by alpha-methyl-DOPA].

Authors: E WESTERMANN; H BALZER; J KNELL
Journal: Naunyn Schmiedebergs Arch Exp Pathol Pharmakol Date: 1958

5. [Effect of a decarboxylase inhibitor on the effects of dopa & dops on blood pressure].

Authors: H DENGLER; G REICHEL
Journal: Naunyn Schmiedebergs Arch Exp Pathol Pharmakol Date: 1957

6. Inhibition of dihydroxy-phenylalanine decarboxylase by derivatives of phenylalanine.

Authors: T L SOURKES
Journal: Arch Biochem Biophys Date: 1954-08 Impact factor: 4.013

7. [alpha-Methyl-DOPA. Therapeutic experiences in hypertension and biochemical research on its mode of action].

Authors: F SCHAUB; F NAGER; H SCHAER; W ZIEGLER; P LICHTLEN
Journal: Schweiz Med Wochenschr Date: 1962-05-19

8. Pharmacodynamic effects and clinical use of alpha methyldopa in the treatment of essential hypertension.

Authors: G ONESTI; A N BREST; P NOVACK; J H MOYER
Journal: Am J Cardiol Date: 1962-06 Impact factor: 2.778

9. Decarboxylase inhibition and blood pressure reduction by alpha-methyl-3,4-dihydroxy-DL-phenylalanine.

Authors: J A OATES; L GILLESPIE; S UDENFRIEND; A SJOERDSMA
Journal: Science Date: 1960-06-24 Impact factor: 47.728

9 in total

8 in total

Review 8. Methyldopa for primary hypertension.

Authors: Greg T Mah; Aaron M Tejani; Vijaya M Musini
Journal: Cochrane Database Syst Rev Date: 2009-10-07

8 in total

Hypotensive action methyldopa.

1. Clinical and chemical studies with alpha-methyl-dopa in patients with hypertension.

2. Clinical pharmacology of newer anthypertensive agents, monoamine oxidase and decarboxylase inhibitors, bretvlium tosvlate, and guanethidine.

3. [Inhibition of DOPA decarboxylase by alpha-methyl-DOPA in vivo].

4. [Inhibition of serotonin formation by alpha-methyl-DOPA].

5. [Effect of a decarboxylase inhibitor on the effects of dopa & dops on blood pressure].

6. Inhibition of dihydroxy-phenylalanine decarboxylase by derivatives of phenylalanine.

7. [alpha-Methyl-DOPA. Therapeutic experiences in hypertension and biochemical research on its mode of action].

8. Pharmacodynamic effects and clinical use of alpha methyldopa in the treatment of essential hypertension.

9. Decarboxylase inhibition and blood pressure reduction by alpha-methyl-3,4-dihydroxy-DL-phenylalanine.

1. Editorial: Side effects of methyldopa.

2. Methyldopa and depression.

3. Bethanidine, Guanethidine, and Methyldopa in Treatment of Hypertension: a Within-patient Comparison.

4. Hyperpyrexia During Treatment with Methyldopa.

5. Comparative study of metoprolol and alpha-methyldopa in untreated essential hypertension.

6. High-performance liquid chromatographic resolution of (R, S)-α-alkyl-α-amino acids as diastereomeric derivatives.

7. SOME OBSERVATIONS ON THE PHARMACOLOGY OF ALPHA-METHYLDOPA.

Review 8. Methyldopa for primary hypertension.